An extensive review of state-of-the-art transfer learning techniques used in medical imaging: Open issues and challenges

Abstract

Abstract Deep learning techniques, which use a massive technology known as convolutional neural networks, have shown excellent results in a variety of areas, including image processing and interpretation. However, as the depth of these networks grows, so does the demand for a large amount of labeled data required to train these networks. In particular, the medical field suffers from a lack of images because the procedure for obtaining labeled medical images in the healthcare field is difficult, expensive, and requires specialized expertise to add labels to images. Moreover, the process may be prone to errors and time-consuming. Current research has revealed transfer learning as a viable solution to this problem. Transfer learning allows us to transfer knowledge gained from a previous process to improve and tackle a new problem. This study aims to conduct a comprehensive survey of recent studies that dealt with solving this problem and the most important metrics used to evaluate these methods. In addition, this study identifies problems in transfer learning techniques and highlights the problems of the medical dataset and potential problems that can be addressed in future research. According to our review, many researchers use pre-trained models on the Imagenet dataset (VGG16, ResNet, Inception v3) in many applications such as skin cancer, breast cancer, and diabetic retinopathy classification tasks. These techniques require further investigation of these models, due to training them on natural, non-medical images. In addition, many researchers use data augmentation techniques to expand their dataset and avoid overfitting. However, not enough studies have shown the effect of performance with or without data augmentation. Accuracy, recall, precision, F 1 score, receiver operator characteristic curve, and area under the curve (AUC) were the most widely used measures in these studies. Furthermore, we identified problems in the datasets for melanoma and breast cancer and suggested corresponding solutions.